Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Ensem Therapeutics
PMV Pharmaceuticals, Inc
Kivu Bioscience Inc.
AstraZeneca
University of California, Irvine
Eli Lilly and Company
ViroMissile, Inc.
Terremoto Biosciences Inc.
Bristol-Myers Squibb
Jazz Pharmaceuticals
AstraZeneca
Arvinas Inc.
Tizona Therapeutics, Inc
Clasp Therapeutics, Inc.
Normunity AccelCo, Inc.
Eli Lilly and Company
IDEAYA Biosciences
DualityBio Inc.
MacroGenics
Avacta Life Sciences Ltd
Institut Curie
SystImmune Inc.
Daiichi Sankyo
Solve Therapeutics
University of Nebraska
Eli Lilly and Company
Adela, Inc
Perspective Therapeutics
Radiopharm Theranostics, Ltd
Innate Pharma
Fate Therapeutics
Tanabe Pharma America, Inc.
Cancer Research UK
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Maastricht University Medical Center
Chongqing Precision Biotech Co., Ltd
LigaChem Biosciences, Inc.
Institut Claudius Regaud
Travera Inc
Jonsson Comprehensive Cancer Center
University of California, Irvine
University Health Network, Toronto
Pack Health
Cancer Research UK
Second Affiliated Hospital of Guangzhou Medical University
Innolake Biopharm
Beijing Friendship Hospital
Hospices Civils de Lyon